Theralase Achieves 98% Destruction of Bladder Cancer

TORONTO, ON  July 22, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX VENTURE: TLT) (TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has achieved near complete destruction (~98%) of bladder cancer in an animal model.

The Company previously announced on December 9th and 23rd, 2014, respectively, of its success in destroying bladder cancer cells both in a Petri dish and in a preliminary orthotopic rat model in research performed at the University of Toledo.

Theralase, in order to optimize the model, relocated it to Princess Margaret Cancer Center, University Health Network ("UHN") under the direction of Dr. Lothar Lilge, Senior Scientist, UHN and Dr. Arkady Mandel, Chief Scientific Officer ("CSO") of the Company. Optimization of both the formulation and purity of the lead drug, TLD-1433, by Sigma Aldridge Fine Chemicals ("SAFC") and the wavelength of laser light used to activate the drug by Theralase resulted in achieving the highest cell kill to date.

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

CALGARY, July 21, 2015  - Resverlogix Corp. ("Resverlogix") (TSX:RVX.TO) announced today that it has closed the previously-announced private placement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") and Eastern Capital Limited ("Eastern").  

Under the terms of the transaction, Hepalink subscribed for 13,270,000 units, each unit ("Unit") being comprised of one (1) common share and 0.075358 common share purchase warrants, for aggregate proceeds of approximately CAD$35 million, or CAD$2.67 per Unit. Each whole warrant is exercisable into one common share at CAD$2.67 per share for a period of five years.

BioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture

LYNBROOK, N.Y., July 20, 2015 -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced that Asahi Kasei Pharma Corporation (Asahi Kasei) has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX^® (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan. Asahi has the rights to develop and market XIAFLEX in Japan through an agreement with BioSpecifics' partner Endo International plc (Endo). BioSpecifics will receive a milestone payment upon commercial launch in Japan.

Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma

- Study Met Primary Endpoint of Significantly Improving Progression-Free Survival -
- Cabozantinib Reduced the Risk of Disease Progression or Death by 42%; Hazard Ratio = 0.58, (p < 0.0001) Compared to Everolimus -
- Overall Survival Interim Analysis Showed a Trend Favoring Cabozantinib; Hazard Ratio = 0.67, (p = 0.005) Compared to Everolimus -
- Exelixis to Complete U.S. and EU Regulatory Filings in Early 2016 -

- Conference Call at 8:30 AM EDT / 5:30 AM PDT Today -

SOUTH SAN FRANCISCO, Calif.-- Exelixis, Inc. (EXEL) today announced positive top-line results from the primary analysis of METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with metastatic renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI).